Completed PHASE3 INTERVENTIONAL NCT00184639

Comparison of Insulin Detemir and Insulin Semilente®MC in Type 1 Diabetes

Comparison of Efficacy and Safety of Insulin Detemir and Insulin Semilente®MC in Children, Adolescents and Young Adults With Type 1 Diabetes on Basal-Bolus Regimen.

Sponsor: Novo Nordisk A/S

Conditions Diabetes Diabetes Mellitus, Type 1

Interventions insulin detemir

Updated 7 times since 2017 Last updated: Feb 22, 2017 Started: Aug 16, 2004 Primary completion: Nov 22, 2005 Completion: Nov 22, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Diabetes and Diabetes Mellitus, Type 1, this trial is completed. The trial is conducted by Novo Nordisk A/S and has accumulated 7 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Mar 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Mar 2017 [monthly]

Completed PHASE3

First recorded

Aug 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany
• Hanover, Germany